International Journal of Drug Policy
Volume 16 , Pages 67-75 , December 2005

Effectiveness of drug dependence treatment in HIV prevention

  • Michael Farrell

      Affiliations

    • National Addiction Centre, Institute of Psychiatry, Kings College London, P.O. Box 48, 4 Windsor Walk, London SE5 8AF, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 2077405701; fax: +44 2077405765.
    • ,
  • Linda Gowing

      Affiliations

    • Drug and Alcohol Services Council and University of Adelaide, Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, Australia
    • Tel.: +61 8 8303 8055; fax: +61 8 8303 8059.
    • ,
  • John Marsden

      Affiliations

    • National Addiction Centre, Institute of Psychiatry, Kings College London, P.O. Box 48, 4 Windsor Walk, London SE5 8AF, UK
    • ,
  • Walter Ling

      Affiliations

    • Department Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA 90025, USA
    • Tel.: +1 310 312 0500x317; fax: +1 310 312 0552.
    • ,
  • Robert Ali

      Affiliations

    • Drug and Alcohol Services Council and University of Adelaide, Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, Australia
    • Tel.: +61 8 8303 8055; fax: +61 8 8303 8059.

Received 11 January 2005 ,Revised 4 February 2005 ,Accepted 6 February 2005.

References 

  1. Ahmadi J. Methadone vs. buprenorphine maintenance for the treatment of heroin-dependent outpatients. Journal of Substance Abuse Treatment. 2003;24:217–220
  2. American Psychiatric Association. (1995). Practice guideline for the treatment of patients with substance use disorders: Alcohol, cocaine, opioids. American Journal of Psychiatry, 152(11 Suppl.), 1–59.
  3. Antela A, Casado JL, Gonzalez MJ, Perez P, Perez-Elias MJ, Montilla P, et al. Influence of a methadone maintenance programme on the improved outcome of a cohort of injecting drug users with advanced HIV disease. AIDS. 1997;11(11):1405–1406
  4. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. American Journal on Addictions. 2004;13(Suppl. 1):S17–S28
  5. Avants SK, Warburton LA, Hawkins KA, Margolin A. Continuation of high-risk behavior by HIV-positive drug users. Treatment implications. Journal of Substance Abuse Treatment. 2000;19(1):15–22
  6. Baker A, Lee NK. A review of psychosocial interventions for amphetamine use. Drug and Alcohol Review. 2003;22(3):323–335
  7. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001;96(5):683–690
  8. Brahen LS, Henderson RK, Capone T, Kordal N. Naltrexone treatment in a jail work-release program. Journal of Clinical Psychiatry. 1984;45(9 Sec. 2):49–52
  9. Bux DA, Lamb RJ, Iguchi MY. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug and Alcohol Dependence. 1995;37(1):29–35
  10. Camacho LM, Bartholomew NG, Joe GW, Cloud MA, Simpson DD. Gender, cocaine and during-treatment HIV risk reduction among injection opioid users in methadone maintenance. Drug and Alcohol Dependence. 1996;41(1):1–7
  11. Carroll KM. Treating drug dependence: Recent advances and old truths. In:  Miller WR,  Heather N editor. Treating addictive behaviours. New York: Plenum Press; 1998;p. 217–229
  12. Cornish JW, Metzger DS, Woody GE, Wilson D, McLellan AT, Vandergrift B, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment. 1997;14(6):529–534
  13. Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Archives of General Psychiatry. 1999;56(6):493–502
  14. Darke S, Swift W, Hall W, Ross M. Drug use HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug and Alcohol Dependence. 1993;34:67–70
  15. Darke S, Ross J, Teesson M, Ali R, Cooke R, Ritter A, et al. Factors associated with 12 months continuous heroin abstinence: Findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment. 2005;28(3):255–263
  16. De Leon G. The therapeutic community: Theory, model, and method. New York, NY, United States: Springer Publishing Co. Inc.; 2000;
  17. Des Jarlais DC, Friedman SR, Woods J, Milliken J. HIV infection among intravenous drug users: Epidemiology and emerging public health perspectives. In:  Lowinson JH,  Ruiz P,  Millman RB,  Langrod JG editor. Substance abuse: A comprehensive textbook. Baltimore: Williams and Wilkins; 1992;p. 734–743
  18. Fiorentine R. After drug treatment: Are 12-step programs effective in maintaining abstinence?. American Journal of Drug and Alcohol Abuse. 1999;25(1):93–116
  19. Fiorentine R, Hillhouse MP. Drug treatment and 12-step program participation: The additive effects of integrated recovery activities. Journal of Substance Abuse Treatment. 2000;18(1):65–74
  20. Gerstein DR, Harwood H. In: CALDATA general report. California Department of Alcohol and Drug Programs. 1994;
  21. Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction. 2004;99(6):697–707
  22. Gossop M, Marsden J, Stewart D. NTORS at one year: Changes in substance use, health and criminal behaviour one year after intake. London: Department of Health; 1998;
  23. Gowing LR, Ali RL, White JM. The management of opioid withdrawal. Drug and Alcohol Review. 2000;19(3):309–318
  24. Gowing L, Cooke R, Biven A, Watts D. Towards better practice in therapeutic communities. Australia: Australasian Therapeutic Communities Association, Canberra; 2002;
  25. Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection [Cochrane Review]. In: The cochrane library (Issue 4). Chichester, UK: John Wiley and Sons Ltd.; 2004;
  26. Gossop M, Marsden J, Stewart D, Edwards C, Lehmann P, Wilson A, et al. The national treatment outcome research study in the United Kingdom: Six-month follow-up of outcomes. Psychology of Addictive Behaviors. 1997;11(4):324–337
  27. Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: A meta-analysis. Drug and Alcohol Dependence. 2000;58(1):55–66
  28. Hall W, Ward J, Mattick RP. The effectiveness of methadone maintenance treatment 1: Heroin use and crime. In:  Ward J,  Mattick RP,  Hall W editor. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers; 1998;p. 17–57
  29. Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors. 1997;11(4):261–278
  30. Johnson RE. Review of US clinical trials of buprenorphine. Research and Clinical Forums. 1997;19(3):17–23
  31. Johnson RE, Strain EC, Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence. 2003;70(Suppl. 2):59–S77
  32. Kelley JL, Petry NM. HIV risk behaviors in male substance abusers with and without antisocial personality disorder. Journal of Substance Abuse Treatment. 2000;19(1):59–66
  33. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence [Cochrane Review]. In: The cochrane library (Issue 3). Chichester, UK: John Wiley and Sons Ltd.; 2003;
  34. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Annals of the New York Academy of Sciences. 2000;909:186–216
  35. Mattick RP, Ward J, Hall W. The role of counselling and psychological therapy. In:  Ward J,  Mattick RP,  Hall W editor. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers; 1998;p. 265–304
  36. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence [Cochrane Review]. In: The cochrane library (Issue 4). Chichester, UK: John Wiley and Sons Ltd.; 2002;
  37. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence [Cochrane Review]. In: The cochrane library (Issue 3). Chichester, UK: John Wiley and Sons Ltd.; 2003;
  38. McCance-Katz EF, Jatlow P, Rainey P, Friedland G. Methadone effects on zidovudine (AZT) disposition (ACTG 262). Journal Acquired Immune Deficiency Syndrome Human Retrovirology. 1998;18:435–443
  39. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. American Journal Addictions. 2001;10:296–307
  40. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified Directly Observed Therapy (MDOT) for injection drug users with HIV disease. American Journal Addictions. 2002;11:271–278
  41. McLellan AT, Arndt IO, Metzger DS, Woody GE, O’Brien CP. The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association. 1993;269(15):1953–1959
  42. O’Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. New England Journal of Medicine. 1994;331(7):450–459
  43. Powell JE, Taylor D. Evaluation of a residential detoxification and motivational program: The Wollongong Crisis Centre. Report of a project funded by the Australian Research Into Drug Abuse Program of the National Campaign Against Drug Abuse. Canberra: Commonwealth of Australia; 1989;
  44. Shearer J, Gowing LR. Pharmacotherapies for problematic psychostimulant use: A review of current research. Drug and Alcohol Review. 2004;23(2):203–211
  45. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: A review. Drug and Alcohol Dependence. 2000;59(1):17–31
  46. Stimson GV. AIDS and injecting drug use in the United Kingdom 1987–1993 the policy response and the prevention of the epidemic. Social Science and Medicine. 1995;41(5):699–716
  47. Swindle RW, Peterson KA, Paradise MJ, Moos RH. Measuring substance abuse program treatment orientations: The Drug and Alcohol Program Treatment Inventory. Journal of Substance Abuse. 1995;7:61–78
  48. Tucker TK, Ritter AJ. Naltrexone in the treatment of heroin dependence: A literature review. Drug and Alcohol Review. 2000;19(1):73–82
  49. UNODC. (2003). Investing in drug abuse treatment. A discussion paper for policy makers. United Nations, New York, United States.
  50. Joint WHO/UNAIDS/UNODC. (2003). Position paper on substitution treatment. Geneva, Switzerland.
  51. Ward J, Mattick RP, Hall W. The use of methadone during maintenance treatment: Pharmacology, dosage and treatment outcome. In:  Ward J,  Mattick RP,  Hall W editor. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers; 1998;p. 205–238
  52. Washton AM, Gold MS, Pottash AC. Naltrexone in addicted physicians and business executives. Journal of Clinical Psychiatry. 1984;45(9):39–41
  53. Weber R, Ledergerber B, Opravil M, Siegenthaler W, Luthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. British Medical Journal. 1990;301(6765):1362–1365
  54. Weiss RD, Griffin ML, Najavits LM, Hufford C, Kogan J, Thompson HJ, et al. Self-help activities in cocaine dependent patients entering treatment: Results from NIDA collaborative cocaine treatment study. Drug and Alcohol Dependence. 1996;43(1–2):79–86
  55. West SL, O’Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. Journal of Substance Abuse. 2000;12(4):405–414
  56. World Health Organization, United Nations Office on Drugs and Crime, & Joint United Nations Programme on HIV/AIDS. (2004). Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: Position paper. Geneva, Switzerland: World Health Organization.
  57. Zador DA, Adams M, Curry KH. Clinical experience with naltrexone maintenance in a hospital drug and alcohol outpatient setting. Medical Journal of Australia. 1999;171(9):501

PII: S0955-3959(05)00084-8

doi: 10.1016/j.drugpo.2005.02.008

International Journal of Drug Policy
Volume 16 , Pages 67-75 , December 2005

Article Tools